{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:24Z","timestamp":1790803584602,"version":"4.1.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["534053725"],"award-info":[{"award-number":["534053725"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.pharmthera.2025.108933","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:36:37Z","timestamp":1759937797000},"page":"108933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment strategies for leptomeningeal disease in patients with breast cancer"],"prefix":"10.1016","volume":"276","author":[{"given":"Lennard","family":"Spanehl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishab","family":"Ramapriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Blitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Heesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibueze D.","family":"Nwagwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian A.","family":"Gessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Valdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya Linda","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal A.","family":"Aizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Bernstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2025.108933_bb0005","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamaoncol.2024.1299","article-title":"Radiation therapy followed by intrathecal Trastuzumab-Pertuzumab for ERBB2-positive breast leptomeningeal disease: A phase 1 nonrandomized controlled trial","volume":"10","author":"Ahmed","year":"2024","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41523-023-00519-0","article-title":"Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan","volume":"9","author":"Alder","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0015","article-title":"Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy","volume":"bcr2016215525","author":"Almajed","year":"2016","journal-title":"BMJ Case Reports"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0020","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11060-021-03827-2","article-title":"Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes","volume":"154","author":"Bander","year":"2021","journal-title":"Journal of Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108933_bb0030","first-page":"242222","article-title":"Radiation absorbed dose to spinal cord: Therapy of leptomeningeal metastasis using Beta-emission radiopharmaceuticals","volume":"65","author":"Bao","year":"2024","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2023.101377","article-title":"Radiation therapy in the Management of Leptomeningeal Disease from Solid Tumors","volume":"9","author":"Barbour","year":"2024","journal-title":"Advances in Radiation Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000537","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","volume":"8","author":"Barsoumian","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0045","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4161\/cbt.7.8.6216","article-title":"Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation","volume":"7","author":"Benencia","year":"2008","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0050","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.28343","article-title":"Intraventricular immunovirotherapy; a translational step forward","volume":"14","author":"Bernstock","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0055","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41388-022-02312-y","article-title":"Targeting oncometabolism to maximize immunotherapy in malignant brain tumors","volume":"41","author":"Bernstock","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4103\/1673-5374.228718","article-title":"Drugging SUMOylation for neuroprotection and oncotherapy","volume":"13","author":"Bernstock","year":"2018","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0065","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/0008-5472.CAN-20-3317","article-title":"Inhibition of Jumonji histone demethylases selectively suppresses HER2(+) breast leptomeningeal Carcinomatosis growth via inhibition of GMCSF expression","volume":"81","author":"Bhan","year":"2021","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0070","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","article-title":"Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic Leukemia","volume":"32","author":"Bhojwani","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fphar.2017.00193","article-title":"Inhibition of VEGF and Angiopoietin-2 to reduce brain metastases of breast cancer burden","volume":"8","author":"Bohn","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0085","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.addr.2021.03.018","article-title":"The past, present, and future of breast cancer models for nanomedicine development","volume":"173","author":"Boix-Montesinos","year":"2021","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1212\/WNL.55.1.117","article-title":"Response of leptomeningeal metastases from breast cancer to hormonal therapy","volume":"55","author":"Boogerd","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0105","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.nucmedbio.2009.04.003","article-title":"Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of \u03b1-particle-emitting 211At-labeled trastuzumab","volume":"36","author":"Boskovitz","year":"2009","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0115","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10585-020-10019-1","article-title":"Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis","volume":"37","author":"Brown","year":"2020","journal-title":"Clinical & Experimental Metastasis"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/JCO.2017.75.9589","article-title":"Whole-brain radiotherapy for brain metastases: evolution or revolution?","volume":"36","author":"Brown","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1517\/13543784.2011.542148","article-title":"Patupilone in cancer treatment","volume":"20","author":"Bystricky","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100150","article-title":"Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database","volume":"6","author":"Carausu","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0145","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1517\/17425247.2013.808184","article-title":"Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood\u2013brain barrier divide","volume":"10","author":"Chacko","year":"2013","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0150","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10072-015-2259-1","article-title":"Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series","volume":"36","author":"Chahal","year":"2015","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1005976926058","article-title":"Leptomeningeal metastases: a review of evaluation and treatment","volume":"37","author":"Chamberlain","year":"1998","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000492","article-title":"Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jfma.2015.03.005","article-title":"Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis","volume":"115","author":"Chen","year":"2016","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0175","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.omtm.2020.03.028","article-title":"Preclinical toxicology of rQNestin34.5v.2: An oncolytic herpes virus with transcriptional regulation of the ICP34.5 Neurovirulence gene","volume":"17","author":"Chiocca","year":"2020","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0180","doi-asserted-by":"crossref","first-page":"693","DOI":"10.6004\/jnccn.2005.0039","article-title":"Leptomeningeal metastases: current concepts and management guidelines","volume":"3","author":"Chowdhary","year":"2005","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0185","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-013-1244-x","article-title":"Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa","volume":"115","author":"Comte","year":"2013","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0190","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06984-1","article-title":"Craniospinal irradiation (CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting","volume":"20","author":"Devecka","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101881","article-title":"Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors","volume":"41","author":"Diaz","year":"2024","journal-title":"Translational Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11060-022-03949-1","article-title":"Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases","volume":"157","author":"Diaz","year":"2022","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","article-title":"Capecitabine therapy of central nervous system metastases from breast cancer","volume":"85","author":"Ekenel","year":"2007","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1097-0215(19990719)82:2<219::AID-IJC12>3.0.CO;2-#","article-title":"Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats","volume":"82","author":"Engebraaten","year":"1999","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","article-title":"The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction","volume":"31","author":"Engelhardt","year":"2009","journal-title":"Seminars in Immunopathology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002800000173","article-title":"Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer","volume":"46","author":"Esteva","year":"2000","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0230","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbrc.2017.02.014","article-title":"SOX10 induced nestin expression regulates cancer stem cell properties of TNBC cells","volume":"485","author":"Feng","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00066-010-2100-y","article-title":"DEGRO practical guidelines for palliative radiotherapy of breast cancer patients: Brain metastases and leptomeningeal Carcinomatosis","volume":"186","author":"Feyer","year":"2010","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-019-05317-6","article-title":"Breast leptomeningeal disease: a review of current practices and updates on management","volume":"177","author":"Figura","year":"2019","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0245","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","article-title":"Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy","volume":"175","author":"Figura","year":"2019","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0250","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-21-3017","article-title":"Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis","volume":"28","author":"Fitzpatrick","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0255","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1038\/s41467-023-43242-x","article-title":"Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype","volume":"14","author":"Fitzpatrick","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0260","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0265","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00066-011-0025-8","article-title":"Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors","volume":"188","author":"Gani","year":"2012","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0270","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of breast cancer patients with meningeal carcinomatosis","volume":"21","author":"Gauthier","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0275","series-title":"Bevacizumab","author":"Gerriets V","year":"2023"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0280","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/0306-4522(96)00281-3","article-title":"Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat","volume":"75","author":"Ghersi-Egea","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0285","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0290","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9","article-title":"Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status","volume":"75","author":"Glantz","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0295","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0300","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archneur.1994.00540170033013","article-title":"Clinical outcome in aggressively treated meningeal carcinomatosis","volume":"51","author":"Grant","year":"1994","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0305","first-page":"1053","article-title":"D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation","volume":"36","author":"Hayashi","year":"2021","journal-title":"Histology and Histopathology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0310","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1073\/pnas.94.3.843","article-title":"The \u03b3 <sub>1<\/sub> 34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1\u03b1 to dephosphorylate the \u03b1 subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by d","volume":"94","author":"He","year":"1997","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0315","first-page":"736","article-title":"Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa","volume":"49","author":"Heideman","year":"1989","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0320","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/PL00002398","article-title":"Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis","volume":"177","author":"Hermann","year":"2001","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2004.05.008","article-title":"Leptomeningeal metastasis: survival and prognostic factors in 155 patients","volume":"223","author":"Herrlinger","year":"2004","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0330","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s10147-020-01668-z","article-title":"Utility of whole brain radiation therapy for leptomeningeal carcinomatosis","volume":"25","author":"Hirano","year":"2020","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0335","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0340","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/0008-5472.CAN-04-3227","article-title":"An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor","volume":"65","author":"Kambara","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0345","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-22-1382","article-title":"Safety and efficacy of intraventricular Immunovirotherapy with oncolytic HSV-1 for CNS cancers","volume":"28","author":"Kang","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0350","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hemonc.2019.08.008","article-title":"High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature","volume":"12","author":"Kapke","year":"2019","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0355","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-010-0434-z","article-title":"Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors","volume":"103","author":"Kiewe","year":"2011","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0360","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12957-019-1595-7","article-title":"Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis","volume":"17","author":"Kim","year":"2019","journal-title":"World Journal of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0365","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41598-017-00862-w","article-title":"Expression of nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer","volume":"7","author":"Kr\u00fcger","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0370","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/neuonc\/noac142","article-title":"Preclinical modeling in leptomeningeal disease: Starting at the foundation to tackle a difficult disease","volume":"24","author":"Kumthekar","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0375","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal Carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0380","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0385","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41417-023-00588-0","article-title":"Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases","volume":"30","author":"Kuruppu","year":"2023","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0390","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41417-018-0060-z","article-title":"A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging","volume":"26","author":"Kuruppu","year":"2019","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0395","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.addr.2004.07.007","article-title":"Efflux transport systems for organic anions and cations at the blood-CSF barrier","volume":"56","author":"Kusuhara","year":"2004","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0400","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000464400","article-title":"Efficacy of liposomal cytarabine in the treatment of leptomeningeal metastasis of breast cancer","volume":"12","author":"Laakmann","year":"2017","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0405","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/neuonc\/noac249","article-title":"Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries","volume":"25","author":"Lamba","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0410","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.addr.2004.07.009","article-title":"Potential role of ABC transporters as a detoxification system at the blood-CSF barrier","volume":"56","author":"de Lange","year":"2004","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0415","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-016-3798-8","article-title":"Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis","volume":"157","author":"Lavaud","year":"2016","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0420","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/neuonc\/noac054","article-title":"A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma","volume":"24","author":"Law","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0425","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/neuonc\/noac043","article-title":"Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0430","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.4103\/2152-7806.111304","article-title":"Carcinomatous meningitis: Leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","journal-title":"Surgical Neurology International"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0435","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","article-title":"A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer","volume":"113","author":"Le Rhun","year":"2013","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0440","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0445","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0455","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.2188","article-title":"Antigen mass may influence Trastuzumab concentrations in cerebrospinal fluid after intrathecal administration","volume":"110","author":"Le Tilly","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0460","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.currproblcancer.2017.07.001","article-title":"The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: A systematic review and pooled analysis","volume":"41","author":"Lee","year":"2017","journal-title":"Current Problems in Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0465","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1475-2867-13-5","article-title":"Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours","volume":"13","author":"Lewis","year":"2013","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0470","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83272","article-title":"VLA-4 suppression by senescence signals regulates meningeal immunity and leptomeningeal metastasis","volume":"11","author":"Li","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0475","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jop.12538","article-title":"Long noncoding RNA MALAT1 affects the efficacy of radiotherapy for esophageal squamous cell carcinoma by regulating Cks1 expression","volume":"46","author":"Li","year":"2017","journal-title":"Journal of Oral Pathology & Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0480","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3171\/2011.5.JNS101768","article-title":"Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study","volume":"115","author":"Lin","year":"2011","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0485","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0490","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide\u2013TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0495","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ctrv.2015.12.004","article-title":"Therapy of leptomeningeal metastasis in solid tumors","volume":"43","author":"Mack","year":"2016","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0500","doi-asserted-by":"crossref","first-page":"7134","DOI":"10.1158\/0008-5472.CAN-13-2051","article-title":"Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis","volume":"73","author":"Magbanua","year":"2013","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0505","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s12094-021-02615-8","article-title":"A systematic review of craniospinal irradiation for leptomeningeal disease: past, present, and future","volume":"23","author":"Maillie","year":"2021","journal-title":"Clinical and Translational Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0510","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0515","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0520","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/0284186X.2012.689857","article-title":"Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases","volume":"52","author":"Martens","year":"2013","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0525","first-page":"208","article-title":"Metronomic Capecitabine effectively blocks leptomeningeal Carcinomatosis from breast cancer: A case report and literature review","volume":"18","author":"Maur","year":"2017","journal-title":"American Journal of Case Reports and Clinical Images"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0530","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.breast.2011.05.007","article-title":"Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis","volume":"20","author":"Mego","year":"2011","journal-title":"The Breast"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/0-387-24199-X_9","article-title":"Radiation therapy for leptomeningeal cancer","author":"Mehta","year":"2005","journal-title":"Leptomeningeal Metastases"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0540","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1634\/theoncologist.2019-IO-S1-s04","article-title":"The role of radiation oncology in Immuno-oncology","volume":"24","author":"Meng","year":"2019","journal-title":"The Oncologist"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0545","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s40425-019-0718-6","article-title":"Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy","volume":"7","author":"Menon","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0550","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0555","doi-asserted-by":"crossref","first-page":"10153","DOI":"10.1128\/JVI.01133-08","article-title":"Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2","volume":"82","author":"Menotti","year":"2008","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0560","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/nov273","article-title":"EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors","volume":"18","author":"Milojkovic Kerklaan","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210074","article-title":"Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study","volume":"14","author":"Mitsuya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0570","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41523-023-00550-1","article-title":"Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer","volume":"9","author":"Morganti","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0575","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-18-3502","article-title":"Phase I study of intermittent high-dose Lapatinib alternating with Capecitabine for HER2-positive breast cancer patients with central nervous system metastases","volume":"25","author":"Morikawa","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0580","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","article-title":"Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis","volume":"17","author":"Morikawa","year":"2017","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0585","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3171\/2023.5.JNS23460","article-title":"Genomic alterations associated with postoperative nodular leptomeningeal disease after resection of brain metastases","volume":"140","author":"Morshed","year":"2024","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0590","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clbc.2019.04.004","article-title":"Phase II study of systemic high-dose methotrexate and intrathecal liposomal Cytarabine for treatment of leptomeningeal Carcinomatosis from breast cancer","volume":"19","author":"Mrugala","year":"2019","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0595","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.1093\/neuros\/nyy542","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on the role of surgery in the management of adults with metastatic brain tumors","volume":"84","author":"Nahed","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0600","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002473","article-title":"Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers","volume":"9","author":"Naidoo","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0605","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-024-01614-1","article-title":"Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and\/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)","volume":"31","author":"Nakayama","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0610","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2021.03.002","article-title":"Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues","volume":"173","author":"Naseri Kouzehgarani","year":"2021","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0615","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1212\/WNL.0b013e31828f183f","article-title":"Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors","volume":"80","author":"Nayak","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0620","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clbc.2014.07.004","article-title":"Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy","volume":"15","author":"Niwi\u0144ska","year":"2015","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0625","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/neuonc\/noac180","article-title":"Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis","volume":"25","author":"Oberkampf","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0630","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2024.42.16_suppl.2018","article-title":"Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results","volume":"42","author":"O\u2019Brien","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0635","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fonc.2018.00509","article-title":"The comparative treatment of intraventricular chemotherapy by Ommaya reservoir vs. lumbar puncture in patients with leptomeningeal Carcinomatosis","volume":"8","author":"de Oca","year":"2018","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0640","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-010-0831-x","article-title":"Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis","volume":"136","author":"Oechsle","year":"2010","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0645","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","article-title":"Kinetics and MR-based monitoring of AAV9 vector delivery into cerebrospinal fluid of nonhuman primates","volume":"13","author":"Ohno","year":"2019","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0650","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0655","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021333","article-title":"Evaluation of imaging findings and prognostic factors after whole-brain radiotherapy for carcinomatous meningitis from breast cancer: A retrospective analysis","volume":"99","author":"Okada","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0660","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10549-011-1417-2","article-title":"Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab","volume":"127","author":"Oliveira","year":"2011","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0665","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdab027","article-title":"Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies","volume":"3","author":"Olsen","year":"2021","journal-title":"Neuro-Oncology Advances"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0670","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s10147-011-0195-5","article-title":"Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2\/HER1-negative breast cancer","volume":"16","author":"Onishi","year":"2011","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0675","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jjco\/hyg046","article-title":"Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection","volume":"33","author":"Ozdogan","year":"2003","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0680","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2012.09.007","article-title":"Ultrasound-mediated blood-brain\/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model","volume":"163","author":"Park","year":"2012","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0685","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5625\/lar.2018.34.4.160","article-title":"Mouse models of breast cancer in preclinical research","volume":"34","author":"Park","year":"2018","journal-title":"Laboratory Animal Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0690","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4143\/crt.2014.234","article-title":"Intrathecal Trastuzumab treatment in patients with breast cancer and leptomeningeal Carcinomatosis","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0695","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3171\/2014.9.JNS13939","article-title":"Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis","volume":"122","author":"Patel","year":"2015","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0700","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3892\/ol.2014.1993","article-title":"Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report","volume":"7","author":"Patel","year":"2014","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0705","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of a Phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent\/progressive glioblastoma Multiforme, anaplastic astrocytoma, or Gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Human Gene Therapy. Clinical Development"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0710","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/neuonc\/not305","article-title":"Phase II trial of patupilone in patients with brain metastases from breast cancer","volume":"16","author":"Peereboom","year":"2014","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0715","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14737175.2023.2295999","article-title":"The early recognition and diagnosis of neoplastic meningitis","volume":"24","author":"Pellerino","year":"2024","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051192","article-title":"Neratinib and Capecitabine for the treatment of leptomeningeal metastases from HER2-positive breast cancer: A series in the setting of a compassionate program","volume":"14","author":"Pellerino","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0725","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11060-010-0268-8","article-title":"Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report","volume":"101","author":"Peroukides","year":"2011","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0730","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hoc.2021.08.009","article-title":"Leptomeningeal disease","volume":"36","author":"Pi\u00f1a","year":"2022","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0735","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","article-title":"Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases","volume":"12","author":"Prakadan","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0740","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0745","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.11.004","article-title":"Altered cancer metabolism in mechanisms of immunotherapy resistance","volume":"195","author":"Ramapriyan","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0750","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000121688","article-title":"Contrast-enhancing meningeal lesions are associated with longer survival in breast cancer-related leptomeningeal metastasis","volume":"3","author":"Regierer","year":"2008","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0755","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41568-024-00700-y","article-title":"The path to leptomeningeal metastasis","volume":"24","author":"Remsik","year":"2024","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0760","article-title":"Leptomeningeal metastatic cells adopt two phenotypic states","volume":"5","author":"Remsik","year":"2022","journal-title":"Cancer Report (Hoboken)"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0765","article-title":"Leptomeningeal anti-tumor immunity follows unique signaling principles","author":"Remsik","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0770","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11060-024-04788-y","article-title":"Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression","volume":"170","author":"Rogawski","year":"2024","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0775","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1215\/S1152851703000334","article-title":"Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy","volume":"6","author":"Rogers","year":"2004","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0780","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis--the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0785","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01058455","article-title":"An experimental model of leptomeningeal metastases employing rat mammary carcinoma cells","volume":"23","author":"Sagar","year":"1995","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0790","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12609-019-00335-1","article-title":"The promise of immunotherapy for breast cancer brain metastases","volume":"11","author":"Sammons","year":"2019","journal-title":"Current Breast Cancer Reports"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0795","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1005936304256","article-title":"Animal models of leptomeningeal metastasis","volume":"38","author":"Schabet","year":"1998","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0800","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-012-0879-3","article-title":"Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors","volume":"109","author":"Segura","year":"2012","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0805","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11910-022-01198-3","article-title":"Advances in the diagnosis and treatment of leptomeningeal disease","volume":"22","author":"Sharma","year":"2022","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0810","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fonc.2017.00220","article-title":"Preclinical modeling and therapeutic avenues for cancer metastasis to the central nervous system","volume":"7","author":"Singh","year":"2017","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0815","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41388-019-0959-3","article-title":"TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment","volume":"39","author":"Sirkisoon","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0820","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.addr.2004.07.008","article-title":"Peptide and peptide analog transport systems at the blood-CSF barrier","volume":"56","author":"Smith","year":"2004","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0825","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euo.2018.09.013","article-title":"Combining immunotherapy with radiotherapy for the treatment of genitourinary malignancies","volume":"2","author":"Solanki","year":"2019","journal-title":"European Urology Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0830","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.expneurol.2015.07.027","article-title":"A balanced view of the cerebrospinal fluid composition and functions: Focus on adult humans","volume":"273","author":"Spector","year":"2015","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0835","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1529-8027.2010.00255.x","article-title":"Metastatic lobular breast adenocarcinoma presenting as cauda equina syndrome","volume":"15","author":"Staff","year":"2010","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0840","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0845","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0850","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.2174\/1381612822666160726112115","article-title":"Potential pathways for CNS drug delivery across the blood-cerebrospinal fluid barrier","volume":"22","author":"Strazielle","year":"2016","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0855","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/cancers12010133","article-title":"Preclinical models of craniospinal irradiation for medulloblastoma","volume":"12","author":"Stripay","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0860","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/JNS\/2008\/108\/2\/0248","article-title":"Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa","volume":"108","author":"Suki","year":"2008","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0865","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1227\/01.NEU.0000341535.53720.3E","article-title":"Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis","volume":"64","author":"Suki","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0870","series-title":"Handbook of clinical neurology","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-811161-1.00013-X","article-title":"Leptomeningeal metastasis","volume":"Vol. 149","author":"Taillibert","year":"2018"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0875","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.clcc.2017.11.003","article-title":"Leptomeningeal carcinomatosis in colorectal cancer: the mayo clinic experience","volume":"17","author":"Taylor","year":"2018","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0880","doi-asserted-by":"crossref","first-page":"83734","DOI":"10.18632\/oncotarget.19634","article-title":"Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer","volume":"8","author":"Terrell-Hall","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0885","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002800000118","article-title":"Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis","volume":"46","author":"Tetef","year":"2000","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0890","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdab162","article-title":"Leptomeningeal disease in neurosurgical brain metastases patients: A systematic review and meta-analysis","volume":"3","author":"Tewarie","year":"2021","journal-title":"Neuro-Oncology Advances"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0895","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3816\/CBC.2006.n.028","article-title":"Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report","volume":"7","author":"Tham","year":"2006","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0900","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0905","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0910","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1038\/s41388-019-0870-y","article-title":"Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance","volume":"38","author":"Totsch","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0915","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.breast.2020.11.019","article-title":"Complete response of leptomeningeal carcinomatosis secondary to breast cancer","volume":"54","author":"Troussier","year":"2020","journal-title":"The Breast"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0920","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/annonc\/mdl056","article-title":"Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - clinical trials group (NCIC-CTG)","volume":"17","author":"Trudeau","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0925","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00005072-197703000-00003","article-title":"Meningeal carcinomatosis: development of an experimental model","volume":"36","author":"Ushio","year":"1977","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0930","article-title":"The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis","volume":"6","author":"Vaz Batista","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0935","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/neuonc\/noz081","article-title":"Nodular leptomeningeal disease after surgery for a brain metastasis-should we be concerned?","volume":"21","author":"Vogelbaum","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0940","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/107327481702400107","article-title":"Surgical treatment for leptomeningeal disease","volume":"24","author":"Volkov","year":"2017","journal-title":"Cancer Control"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0945","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","article-title":"Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients","volume":"49","author":"Wasserstrom","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0950","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40263-022-00975-5","article-title":"Leveraging molecular and immune-based therapies in leptomeningeal metastases","volume":"37","author":"Wilcox","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0955","first-page":"2","article-title":"High-dose N,N\u2032,N\u2033-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies","volume":"17","author":"Wolff","year":"1990","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0960","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.clbc.2021.11.002","article-title":"Diagnosis of leptomeningeal metastasis in women with breast cancer through identification of tumor cells in cerebrospinal fluid using the CNSide\u2122 assay","volume":"22","author":"Wooster","year":"2022","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0965","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1290-1","article-title":"A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis","volume":"15","author":"Wu","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-019-1376-z","article-title":"Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis","volume":"14","author":"Yan","year":"2019","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0975","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.22.01148","article-title":"Randomized phase II trial of proton Craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis","volume":"40","author":"Yang","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0980","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","article-title":"Clinical trial of proton craniospinal irradiation for leptomeningeal metastases","volume":"23","author":"Yang","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0985","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.gt.3302319","article-title":"Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer","volume":"11","author":"Yang","year":"2004","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0990","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","article-title":"Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis","volume":"139","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2025.108933_bb0995","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108933_bb1000","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/1759-7714.13450","article-title":"LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1Aexpression via sequestering miR-449b-5p","volume":"11","author":"Zhang","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.pharmthera.2025.108933_bb1005","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1111\/jcmm.13688","article-title":"Transcription factor ATF3 mediates the radioresistance of breast cancer","volume":"22","author":"Zhao","year":"2018","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2025.108933_bb1010","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-014-0408-8","article-title":"Nestin positively regulates the Wnt\/\u03b2-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells","volume":"16","author":"Zhao","year":"2014","journal-title":"Breast Cancer Research"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:21:23Z","timestamp":1766060483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":202,"alternative-id":["S0163725825001457"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108933","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies for leptomeningeal disease in patients with breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108933"}}